Supernus Pharmaceuticals, Inc.Company Review & Valuation

SUPN
Nasdaq
Latest Price
20.04USD
Market Capitalization
1,052.77mUSD

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; aShow morend Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.Show less

Industry
Drug Manufacturers - Specialty & Generic
HQ Location
Rockville, Maryland

Stock Price

Price data not available for Supernus Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

BioGaia
Teva Pharmaceutical Industries Limited
Merck
Eisai

back to top